G1 Overview

G1 is developing novel therapeutics for the treatment of cancer. Our two clinical-stage candidates – trilaciclib and G1T38 – are potent, selective inhibitors of the validated kinase target CDK4/6. Trilaciclib and G1T38 were designed to serve as the backbone of combination treatment regimens in most types of cancer, and to enhance the anti-tumor activity of many current therapies. We are also advancing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer.

G1’s internal team and scientific/clinical advisors have a deep understanding of the biology of cyclin-dependent kinases (CDKs), and extensive drug discovery and clinical oncology development experience.